Deuterium-substituted L-DOPA

Ligand id: 8611

Name: Deuterium-substituted L-DOPA

Abbreviated name: D3 L-DOPA

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 3
Hydrogen bond donors 4
Rotatable bonds 3
Topological polar surface area 103.78
Molecular weight 197.07
XLogP -2.11
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
IUPAC Name
(2S)-2-amino-2,3,3-trideuterio-3-(3,4-dihydroxyphenyl)propanoic acid
Synonyms
DP-102
Database Links
GtoPdb PubChem SID 252166812
PubChem CID 76955701
Search Google for chemical match using the InChIKey WTDRDQBEARUVNC-QZRTVAIESA-N
Search Google for chemicals with the same backbone WTDRDQBEARUVNC
Search UniChem for chemical match using the InChIKey WTDRDQBEARUVNC-QZRTVAIESA-N
Search UniChem for chemicals with the same backbone WTDRDQBEARUVNC
Comments
Chronic treatment with a substantially lower dose of deuterium-substituted L-DOPA (D3-L-DOPA), compared with L-DOPA, (levodopa) produced equal anti-parkinsonian effect and reduced dyskinesia in 6-OHDA-lesioned rats [2] . This new rat study reports similar effect produced by D3-L-DOPA and selegiline plus L-DOPA, respectively, implying adjuvant MAO-B inhibitor treatment may not be necessary with D3-L-DOPA [1]. This compound was proposed for development by the Michael J Fox foundation but there is no clinicaltrials.gov entry.